Medical radionuclide / Optimisation of production route / Nuclear reaction cross section / Standardisation of data / Alternative routes for production of 99m Tc and 68 Ga / Non-standard positron emitter / Novel therapeutic radionuclide Summary. Nuclear reaction cross section data are of great significance in optimisation of production routes of radionuclides. This article deals with some newer aspects of data research related to production of both standard and novel radionuclides. The recent work to standardise the known data is discussed and new measurements with regard to further optimisation of production routes of some commonly used radionuclides are mentioned. Attempts to increase the specific activity of some reactor-produced radionuclides through the use of charged-particle induced reactions are outlined. The jeopardy in the supply of 99m Tc via a fission-produced 99 Mo/ 99m Tc generator is considered and its possible direct production at a cyclotron is briefly discussed. Regarding the novel radionuclides, development work is presently focussed on non-standard positron emitters for diagnosis and on low-range highly ionising radiation emitters for internal radiotherapy. Recent nuclear reaction cross section measurements related to the production of the two types of radionuclides are briefly reviewed and some anticipated trends in nuclear data research are considered.
Introduction
Radionuclides find application in both medical diagnosis and internal radiotherapy [cf . 1] . A suitable radionuclide in a proper chemical form is generally administered into the human body to allow diagnostic studies or to induce therapeutic effect. The underlying principle of in vivo medical diagnosis is that the radiation dose to the patient is minimum. This is achieved through imaging of the human organ from outside of the body using short-lived radionuclides, emitting predominantly a gamma ray in the energy range of 70-250 keV or a positron. The low-energy gamma ray facilitates single photon emission computed tomography (SPECT), and the positron emitter allows positron emission tomography (PET). In contrast to diagnosis, internal radio-*E-mail: s.m.qaim@fz-juelich. de. therapy stipulates that a certain radiation dose is specifically deposited in the malignant tissue. This is brought about through the use of radionuclides emitting corpuscular radiation, i.e., alpha-or beta-particles, or Auger and conversion electrons, in combination with a targeted-compound labelled with the radionuclide. In all those applications a knowledge of nuclear data plays an important role. Whereas the radioactive decay data are of importance in the choice of a radionuclide for a particular diagnostic or therapeutic application, the nuclear reaction cross section data are of great significance in optimisation of the production route of a desired radionuclide (for earlier reviews [cf . [2] [3] [4] [5] [6] [7] ).
The production of radionuclides is carried out using nuclear reactors as well as cyclotrons. In reactor production generally (n, γ ) and (n, f ) processes are utilized. Occasionally (n, p) and double neutron capture reactions are also used. The radioactive products are often neutron excess radionuclides. They mostly decay by β − emission and are therefore especially suited for internal radiotherapy. The cyclotron produced radionuclides, on the other hand, are mainly neutron deficient and decay by electron capture (EC) or β + emission. They are therefore ideally suited for diagnostic studies. The positron emitters are almost exclusively produced using charged-particle accelerators. For production of some radionuclides both nuclear reactors and cyclotrons (accelerators) are extensively used.
This article deals with nuclear reaction cross section data for production of medical radionuclides, with emphasis on some newer aspects. The progress made within the last decade is briefly mentioned. It is not the aim of this short review to enlist all recent publications in the field; instead some typical examples for each aspect are given. Some anticipated trends in nuclear data research are outlined.
Standardisation of data
A vast amount of experimental data is available in the EXFOR file, coordinated by the IAEA. In the case of neutron-induced reactions, the data have been extensively evaluated and standardised, mainly in the context of energy research, and the recommended data are available in several data files (cf . ENDF/B-VII). Those data are useful also for radionuclide production in reactors. Despite this progress, there was still need of evaluation and standardisation of data for many of the reactor-produced therapeutic radionuclides. Also for charged-particle induced reactions used in radionuclide production, generally a large number of measurements were available in the literature. However, no serious evaluation effort was reported. The IAEA embarked on this mission about 16 years ago and organised two successive co-ordinated research programmes (CRPs) in which about a dozen laboratories participated. Since no evaluation methodology existed at that time for charged-particle induced reactions, the initial work was rather empirical. It involved normalisation of the data (in case of outdated decay intensities and monitor cross sections), simple nuclear model calculations and statistical fitting of the data. However, in later years strong application of nuclear models could be built in. The evaluated and recommended data for the major diagnostic radionuclides are now available in [8] and those for the therapeutic radionuclides in [9] . The latter includes both reactor and cyclotron produced therapeutic radionuclides. The standardised data should now allow a proper selection of the projectile energy range in a target to ensure high radionuclidic purity of the desired product. In addition, theoretical yields of the desired radionuclide and the accompanying radioactive impurities can be accurately calculated from the evaluated excitation functions. A few groups are now also individually engaged in this type of studies [cf . 10, 11] . Further work on the validation of evaluated data as well as on the evaluation of data for other emerging radionuclides is necessary.
Optimisation studies relevant to production routes of some standard radionuclides
During the standardisation work it was found that the production data of some commonly used radionuclides were rather discrepant or lacked the required accuracy, calling upon more precise measurements. In a few other cases it was realized that the data for the formation of some impurities needed more attention. A brief account of some newer measurements is given below. With regard to the standard PET radionuclides, some measurements were done relevant to the production of 11 13 N, respectively [12] . The results are shown in Fig. 1 . Those data make it possible to calculate the two radioactive impurities formed during the production of 11 C. For the optimum proton energy range within the nitrogen gas target (E p = 13 → 4 MeV) it is estimated that the 11 C formed will contain about 20%
14 O and 5% 13 N at the end of irradiation. Similarly for the production of 18 F (T 1/2 = 110 min) via the 18 O( p, n) 18 F reaction, the cross section database was extended up to 30 MeV [13] , so that large scale production of this radionuclide using medium-sized cyclotrons could be carried out. Furthermore, measurements on the formation of some short-lived positron emitters were extended up to proton energies of about 200 MeV [14] . However, the highenergy data are of more relevance to proton therapy than to radionuclide production. Some discrepancies existed in the data for the production of the radionuclides 68 Ge (T 1/2 = 270 d) and 82 Sr (T 1/2 = 25.5 d) which are used as parents of the generatorproduced commonly used β + emitting radionuclides 68 Ga (T 1/2 = 1.13 h) and 82 Rb (T 1/2 = 1.3 min), respectively. They are employed especially at PET centres without a cyclotron. A recent measurement on the nat Rb( p, x) 82 Sr reaction [15] solved the discrepancy about the production data of 82 Sr; the measured and calculated thick target yields of 82 Sr over different energy ranges were found to be in good agreement [15] . Regarding the production of 68 Ge via the nat Ga( p, x)-process, a very recent measurement of the excitation function has strengthened the database [16] .
As far as the SPECT radionuclides are concerned, the production data for all five commonly used radionuclides, viz.
123 I (T 1/2 = 13.2 h) and 201 Tl (T 1/2 = 73.0 h), are generally well known. Whereas the radionuclide 99m Tc is mostly obtained via a fission-produced 99 Mo/ 99m Tc generator system, the other four radionuclides are produced using a medium-sized cyclotron. Only in a few special cases some data problems existed. Xe( p, pn) 123 Xe → 123 I. Whereas the data for the first route are well established, there exists some discrepancy in the case of direct formation of 123 Xe. The effect of the discrepancy on the routine production of 123 I is, however, of little significance. The level of the only radionuclidic impurity 121 I (T 1/2 = 2.1 h) is negligibly small. However, it has been recently shown [17] that if the incident proton energy exceeds 30 MeV, the cross section of the process 124 Xe( p, x) 121 I becomes appreciable. The latter decays to long-lived 121 Te (T 1/2 = 154 d) which is a disadvantage. An energy control of the beam incident on the target is therefore mandatory. It has been suggested to limit the beam energy to 35 MeV and reduce the 121 Te content by adapting cooling times [17] .
For calibration of SPECT machines the long-lived radionuclide 57 Co (T 1/2 = 271 d) is commonly used. Some new cross section measurements relevant to its production in nocarrier-added form [18] have strengthened the database. [19, 20] using a 14 MeV d(Be) neutron source. A discussion of the results led to the conclusion that higher yields of those radionuclides would be obtained using a spallation neutron source than the present day fission reactors. Cross section measurements on the production of a few therapeutic radionuclides in a nuclear reactor have also been reported [cf . 21, 22] .
Attempts to improve the specific activity of some reactor-produced therapeutic radionuclides
Many of the therapeutic radionuclides are produced in a nuclear reactor, generally via the (n, γ ) process, and the specific activity (i.e. the radioactivity/unit mass of all isotopes of the element present) achieved is rather low. Some of them can be obtained in no-carrier-added form through precursor decay, generator formation, (n,charged particle) nuclear reaction or fission process. 67 Cu processes does not provide products of sufficient purity. In recent years, therefore, charged-particle induced reactions have been extensively investigated, especially at Brussels, Debrecen and Jülich, to explore the production of those radionuclides in no-carrier-added form. In particular for 64 Cu and 103 Pd a large number of reactions have been studied [for recent reviews cf . 9, 11, 23], out of which the 64 Ni( p, n) 64 Cu and 103 Rh( p, n) 103 Pd processes have been successfully developed for large scale production of the two radionuclides. For 67 Cu and 186 Re, the methods are still in development (see below). Regarding the other above mentioned radionuclides, the investigated processes [cf . [24] [25] [26] [27] [28] [29] [30] are not economical because the resulting yields are too low. The radionuclide 192 Ir is used in brachytherapy and the radionuclide 169 Yb is a potential candidate for brachytherapy. For that purpose the reactor production is adequate. Regarding 169 Er, the real application needs to be demonstrated. The main problem regarding the specific activity is thus presently with 153 Sm which is now often used in internal radiotherapy. For this radionuclide, the use of the 150 Nd(α, n)-reaction on a highly enriched target appears to be of some promise. The measured excitation function [31] is shown in Fig. 2 . The yield of 153 Sm over the energy range E α = 25 → 15 MeV amounts to 2.2 MBq/μA h, with no significant impurity. Thus a high specific-activity and high radionuclidic-purity product could be obtained in a quantity sufficient for medical application, but the cost would be rather high. 
Security of supply of
99m Tc and 68 Ga: search for alternative production routes
The generator-produced radionuclide 99m Tc (T 1/2 = 6.0 h) is the most commonly used agent in diagnostic studies. Its supply is rather jeopardized due to increasing uncertainty in availability of the fission-produced 99 Mo (T 1/2 = 66.0 h) for preparation of generators (ageing reactors, problem with using highly-enriched 235 U as target material, etc.). An intense search for alternative routes of production of 99 Mo and 99m Tc has therefore been going on for more than a decade.
Several routes have been suggested and their cross sections have been measured (for a recent review [cf . 7]).
Out of all those processes the direct production of 99m Tc via the 100 Mo( p, 2n)-reaction appears to be more promising. Several measurements have been reported in recent years [32] [33] [34] [35] [36] and the data show large scatter, especially over the energy range of 10-20 MeV. Nuclear model calculations show [37] that the more recent data [33] [34] [35] [36] are consistent. An evaluation has produced a recommended set of cross sections [37] , which should allow calculation of the yield with enhanced confidence. Over the suitable energy range of E p = 22 → 10 MeV, the calculated yield of 99m Tc amounts to 700 MBq/μA h. Technical efforts to produce 99m Tc via this route are now underway. The levels of long-lived impurities and their implications on the pharmaceutical quality of 99m Tc, however, need to be extensively investigated.
Besides 99m Tc, the availability of the radionuclide 68 Ga (T 1/2 = 1.1 h) is also causing some concern. It is a β + emitting generator-produced radionuclide and is finding increasing application in PET studies, especially in developing countries. The parent radionuclide 68 Ge (T 1/2 = 270 d) is a relatively long-lived cyclotron product and there could be jeopardy about its supply. Some studies on the direct production of 68 Ga via the 68 Zn( p, n) 68 Ga and 65 Cu(α,n) 68 Ga reactions have been reported [cf . 38] . The prospects of direct production of 68 Ga are good but, due to low yield, the adopted procedure will remain limited to in-house use.
Research-oriented radionuclides
Constant research work is going on with the aim to develop novel radionuclides for newer applications in medicine, both diagnostic and therapeutic. Many of the nuclear data studies are, however, only of academic interest, with little chances of real application. The more important developments in the two directions are treated below separately.
Non-standard positron emitters
In view of the enhancing significance of PET, considerable efforts have been devoted over the last 30 years towards development of a large number of non-standard, i.e. non-conventional positron emitters. There have been two motivations: a) study of slow metabolic processes; b) quantification of imaging and dosimetry. Two detailed review articles [6, 39] have recently been published on the development of about 25 novel positron emitters. In this article, therefore, only some salient features related to nuclear data work are discussed.
Out of all non-standard positron emitters recently developed, three radionuclides, viz.
64 Cu (T 1/2 = 12.7 h), 124 I (T 1/2 = 4.2 d) and 86 Y (T 1/2 = 16.0 h), are finding worldwide application. They are opening new perspectives in radioimmunotherapy and radiation dosimetry. The commonly used production method in each case is the low-energy ( p, n) reaction on the respective highly-enriched target nucleus. The basic data in all three cases were measured at the Forschungszentrum Jülich [40] [41] [42] . Although extensive development work related to targetry and chemical separation of those radionuclides has been done in many laboratories (for review cf. [6, 7] ), only one new data measurement has been reported for the 64 Ni( p, n) 64 Cu reaction [43] . On the other hand, for the three radionuclides under discussion, intermediate energy-reactions have been investigated by several groups [cf . 10, 41, [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] and data evaluation has also been performed [cf . 9, 10, 23, 55, 56] . Nonetheless, it is concluded that for each of those three radionuclides the respective ( p, n) reaction gives the purest product, though the yield is not very high.
Besides the above mentioned three established nonstandard positron emitters, there is great potential interest in other positron emitters as well, e.g. 72 As (T 1/2 = 26.0 h), [57] [58] [59] [60] [61] [62] .
As an example, we consider the data for the production of 76 Br [59, 60] . An evaluation has been done [63] and from the recommended cross sections the yields of 76 Br via three reactions, namely 76 Se( p, n) 76 Br, 77 Br( p, 2n) 76 Br and 78 Se( p, 3n) 76 Br, were calculated. The results are reproduced in Fig. 3 . The method for production of this radionuclide could thus be chosen according to the proton energy available at the cyclotron. In practice, however, the 76 Se( p, n) 76 Br reaction is preferred because of the lowest level of the 77 Br (T 1/2 = 56.0 h) impurity. Measurements have also been reported on parent radionuclides of some potentially useful positron emitting generator radionuclides (e.g. 44 Ti (60.4 a)/ 44 Sc (3.9 h)); 62 Zn (9.1 h)/ 62 Cu (9.7 min), etc. [64, 65] . Further extensive cross section data work on many radionuclides is continuing in several laboratories.
Novel therapeutic radionuclides
The new trend in internal radionuclide therapy is to make use of radionuclides emitting low-range but highly ionising radiation, i.e. low-energy alpha-and beta-particle emitters, X-ray emitters or Auger electron emitters. The topic has been discussed in some detail in a recent article [7] . In the present contribution, therefore, only a few selected aspects are dealt with.
Among the β − emitters, the radionuclides 67 Cu (T 1/2 = 2.58 d; E β − = 577 keV) and 186 Re (T 1/2 = 3.72 d; E β − = 1070 keV) have been receiving enhanced attention. Radiochemical measurements [cf . 66] showed that a highly enriched 68 Zn target and the energy range E p = 70 → 30 MeV lead to 67 Cu of high quality. Two other new measurements on the reactions 64 [69] [70] [71] [72] [73] [74] . An analysis of those data was carried out [9, 75] and the result is given in Fig. 4 . Calculations done using the three nuclear model codes, namely STAPRE, EMPIRE and TALYS, reproduce most of the data well [75] . From a critical discussion it was concluded [75] that for obtaining high-purity 186 Re, an enriched 186 W target is absolutely necessary and the maximum proton energy should not exceed 18 MeV.
Among the potentially useful X-ray and Auger electron emitters, the radionuclides 131 [79] .
The radionuclides 193m Pt and 195m Pt are pure X-ray and Auger electron emitters, each decay leading to more than 30 secondary electrons. Thus both those radionuclides have great potential in Auger electron therapy. In a recent study it could be shown that small amounts of 195m Pt can be produced with high specific activity via the 192 Os(α,n) 195m Pt reaction [80] . Using the same target but higher energy α-particles, on the other hand, it was found that 193m Pt of high specific activity could be advantageously produced through the 192 Os(α,3n) 193m Pt reaction [81] . Over the optimum energy range E α = 40 → 30 MeV, this radionuclide can be produced in quantities sufficient for therapeutic applications.
Regarding targeted α-particle therapy, the radionuclide 211 At (T 1/2 = 7.2 h; E α = 5870 keV) has been under investigation for quite some time. Its production data via the 209 Bi(α,2n) 211 At reaction are well known. Presently there is great demand for the radionuclide 225 Ac (T 1/2 = 10.0 d; E α = 5830 keV) which is useful in itself as well as for providing 213 Bi (T 1/2 = 46 min; E α = 5900 keV) through a generator system. In recent years some interest has also developed in 226 Th (T 1/2 = 31 min; E α = 6340 keV) and 223 Ra (T 1/2 = 11.43 d; E α = 5720 keV). Extensive effort is presently being invested in the development of 225 Ac. On one hand its separation from nuclear waste ( 229 Th) is being optimised and, on the other, the 226 Ra( p, 2n) 225 Ac reaction, making use of the radioactive target material 226 Ra, is being developed [cf . 82] . A third possibility under investigation is its production via irradiation of 232 Th with intermediate energy protons [83] [84] [85] . The yield of 225 Ac and the level of the 227 Ac (T 1/2 = 21.8 a) impurity calculated from the recently reported data [83] are given in Fig. 5 . At a proton energy 
Conclusions
Radionuclide production technology is well established and the relevant nuclear data for production of the commonly used radionuclides have been standardised. Yet some nuclear data activities are continuously underway to improve the quality of the products, i.e. either decrease the level of radioactive impurities or improve the specific activity of the product. In recent years, considerable effort has been devoted to searching for alternative routes for the production of 99m Tc. The major thrust of the nuclear data research today is, however, towards developing non-conventional novel positron emitters and therapeutic radionuclides. The nonstandard metallic positron emitters are opening new perspectives in radioimmunotherapy and quantitative radiation dosimetry. The use of low-range but highly ionising radiation in targeted therapy is attracting great attention. It is anticipated that nuclear data work related to the development of the two types of radionuclides will continue also in the future. Newer medical applications, e.g. multimode imaging, combination of radioactivity with nanotechnology, etc., will demand novel radionuclides. For their production, applica-tion of intermediate energy cyclotrons, accelerating all four light charged particles, viz. p, d, 3 He and 4 He, may be necessary. In particular, an intermediate energy α-particle beam holds great promise for producing high-spin isomers which decay by Auger electron emission and are thus potentially very interesting for Auger therapy.
